U-shaped relationship between vitamin D levels and long-term outcome in large cohort of survivors of acute myocardial infarction

International Journal of Cardiology

Volumn 223, Issue , 2016, Pages 962-966

  Aleksova, Aneta ^a   Beltrami, Antonio Paolo ^b   Belfiore, Rita ^a   Barbati, Giulia ^a   Di Nucci, Milena ^c   Scapol, Sara ^a   De Paris, Valerio ^a   Carriere, Cosimo ^a   Sinagra, Gianfranco ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Acute myocardial infarction; Long term mortality; Outcome; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VITAMIN D;

ACUTE HEART INFARCTION; AGE; AGED; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; FEMALE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SURVIVOR; VITAMIN BLOOD LEVEL; AREA UNDER THE CURVE; BLOOD; HEART INFARCTION; ITALY; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SURVIVAL ANALYSIS; TIME; TIME FACTOR; VITAMIN D DEFICIENCY;

AGED; AREA UNDER CURVE; COHORT STUDIES; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME; TIME FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84984617667     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.08.322     Document Type: Article

References (39)

1. [1] Durup, D., et al. A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J. Clin. Endocrinol. Metab. 97:8 (2012), 2644–2652.
2. [2] Lee, J.H., et al. Prevalence of vitamin D deficiency in patients with acute myocardial infarction. Am. J. Cardiol. 107:11 (2011), 1636–1638.
3. [3] Aleksova, A., et al. Vitamin D deficiency in patients with acute myocardial infarction: an Italian single-center study. Int. J. Vitam. Nutr. Res. 85:1–2 (2015), 23–30.
4. [4] De Metrio, M., et al. Vitamin D plasma levels and in-hospital and 1-year outcomes in acute coronary syndromes: a prospective study. Medicine (Baltimore), 94(19), 2015, e857.
5. [5] Pilz, S., et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J. Clin. Endocrinol. Metab. 93:10 (2008), 3927–3935.
6. [6] Khalili, H., Talasaz, A.H., Salarifar, M., Serum vitamin D concentration status and its correlation with early biomarkers of remodeling following acute myocardial infarction. Clin. Res. Cardiol. 101:5 (2012), 321–327.
7. [7] Dobnig, H., et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 168:12 (2008), 1340–1349.
8. [8] Melamed, M.L., et al. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 168:15 (2008), 1629–1637.
9. [9] Johansson, H., et al. Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden. Osteoporos. Int. 23:3 (2012), 991–999.
10. [10] Bjelakovic, G., et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst. Rev., 1, 2014, CD007470.
11. [11] Durup, D., et al. A reverse J-shaped association between serum 25-hydroxyvitamin D and cardiovascular disease mortality: the CopD study. J. Clin. Endocrinol. Metab. 100:6 (2015), 2339–2346.
12. [12] Sempos, C.T., et al. Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the U.S. nationally representative NHANES. J. Clin. Endocrinol. Metab. 98:7 (2013), 3001–3009.
13. [13] Ng, L.L., et al. Vitamin D and prognosis in acute myocardial infarction. Int. J. Cardiol. 168:3 (2013), 2341–2346.
14. [14] Thygesen, K., et al. Third universal definition of myocardial infarction. J. Am. Coll. Cardiol. 60:16 (2012), 1581–1598.
15. [15] Grambsch, P.M., Thereneau, T.M., Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:3 (1994), 515–526.
16. [16] Blanche, P., Dartigues, J.F., Jacqmin-Gadda, H., Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat. Med. 32:30 (2013), 5381–5397.
17. [17] Uno, H., et al. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Stat. Med. 32:14 (2013), 2430–2442.
18. [18] Nibbelink, K.A., et al. 1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte. J. Steroid Biochem. Mol. Biol. 103:3–5 (2007), 533–537.
19. [19] Zittermann, A., Vitamin D and disease prevention with special reference to cardiovascular disease. Prog. Biophys. Mol. Biol. 92:1 (2006), 39–48.
20. [20] Park, C.W., et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 33:1 (1999), 73–81.
21. [21] Boxer, R.S., et al. The effect of vitamin d on aldosterone and health status in patients with heart failure. J. Card. Fail. 20:5 (2014), 334–342.
22. [22] Li, Y.C., et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 110:2 (2002), 229–238.
23. [23] Rahman, A., et al. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J. Steroid Biochem. Mol. Biol. 103:3–5 (2007), 416–419.
24. [24] Russel, R.M., Suter, P.M., Vitamin and trace mineral deficiency and excess. Longo, D.L., et al., (eds.) Harrison's Principles of Internal Medicine, 2012, McGraw Hill, 594–605.
25. [25] Ohsawa, M., et al. 1alpha,25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation 102:23 (2000), 2867–2872.
26. [26] Al-Rasheed, N.M., et al. Vitamin D attenuates pro-inflammatory TNF-alpha cytokine expression by inhibiting NF-small ka, CyrillicB/p65 signaling in hypertrophied rat hearts. J. Physiol. Biochem. 71:2 (2015), 289–299.
27. [27] Ogard, C.G., et al. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. Clin. Endocrinol. 63:5 (2005), 493–498.
28. [28] Bjorkman, M.P., Sorva, A.J., Tilvis, R.S., Elevated serum parathyroid hormone predicts impaired survival prognosis in a general aged population. Eur. J. Endocrinol. 158:5 (2008), 749–753.
29. [29] Yamamoto, M., et al. Vitamin D deficiency and renal calcium transport in the rat. J. Clin. Invest. 74:2 (1984), 507–513.
30. [30] de Boer, I.H., et al. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J. Am. Soc. Nephrol. 20:8 (2009), 1805–1812.
31. [31] Drueke, T.B., Massy, Z.A., Role of vitamin D in vascular calcification: bad guy or good guy?. Nephrol. Dial. Transplant. 27:5 (2012), 1704–1707.
32. [32] Nicoll, R., Cardiovascular calcification and bone: a comparison of the effects of dietary and serum calcium, phosphorous, magnesium and vitamin D., 1(5), 2014, 10 (2014).
33. [33] Baldock, P.A., et al. Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast. J. Bone Miner. Res. 21:10 (2006), 1618–1626.
34. [34] Secchiero, P., et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 210:1 (2010), 274–277.
35. [35] Secchiero, P., et al. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells 26:11 (2008), 2955–2963.
36. [36] Looker, A.C., et al. Vitamin D status: United States, 2001–2006. NCHS Data Brief 59 (2011), 1–8.
37. [37] Bischoff-Ferrari, H.A., et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 84:1 (2006), 18–28.
38. [38] Ross, A.C., et al. Dietary Reference Intakes for Calcium and Vitamin D. 2011, National Academies Press.
39. [39] McKibben, R.A., et al. Factors associated with change in 25-hydroxyvitamin D levels over longitudinal follow-up in the ARIC study. J. Clin. Endocrinol. Metab. 101:1 (2016), 33–43.